Author: Kim, Yu-Jin; Venturini, Victor; de la Torre, Juan C.
Title: Progress in Anti-Mammarenavirus Drug Development Cord-id: xlaq1lq7 Document date: 2021_6_22
ID: xlaq1lq7
Snippet: Mammarenaviruses are prevalent pathogens distributed worldwide, and several strains cause severe cases of human infections with high morbidity and significant mortality. Currently, there is no FDA-approved antiviral drugs and vaccines against mammarenavirus and the potential treatment option is limited to an off-label use of ribavirin that shows only partial protective effect and associates with side effects. For the past few decades, extensive research has reported potential anti-mammarenaviral
Document: Mammarenaviruses are prevalent pathogens distributed worldwide, and several strains cause severe cases of human infections with high morbidity and significant mortality. Currently, there is no FDA-approved antiviral drugs and vaccines against mammarenavirus and the potential treatment option is limited to an off-label use of ribavirin that shows only partial protective effect and associates with side effects. For the past few decades, extensive research has reported potential anti-mammarenaviral drugs and their mechanisms of action in host as well as vaccine candidates. This review describes current knowledge about mammarenavirus virology, progress of antiviral drug development, and technical strategies of drug screening.
Search related documents:
Co phrase search for related documents- act factor and acute infection: 1, 2, 3
- action different mechanism and acute infection: 1, 2
- action drug mechanism and acute infection: 1
- action mechanism and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
Co phrase search for related documents, hyperlinks ordered by date